 About Entrez
Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
My
NCBI (Cubby)
Related Resources
Order Documents
NLM Catalog
NLM
Gateway
TOXNET
Consumer
Health
Clinical Alerts
ClinicalTrials.gov
PubMed
Central |
|
 |
|
-
Comparative bioavailability of
various thiamine derivatives after oral
administration.
Greb A, Bitsch
R.
Department of Human Nutrition, Institute of Nutrition and
Environment, Friedrich Schiller University, Jena, Germany.
In a
multiple change-over study the bioequivalence of 3 thiamine
preparations, used therapeutically as neurotropic agents for the
treatment of polyneuropathies, was tested in a collective of 7
volunteers. After ingestion of a single dose of either 100 mg
benfotiamin CS-benzoylthiamine-o-monophosphate), fursultiamin
(thiamintetrahydrofurfuryldisulfide) or thiaminedisulfide, thiamine
blood levels were analyzed for a 10-hour period. Thiamine was measured
by HPLC after precolumn derivatization to thiochrome. The maximal
thiamine concentration Cmax and its time (tmax) in plasma and
hemolysate, the area under concentration time curve (AUC), and thiamine
excretion in 24-hour urine were assessed as criteria of bioavailability.
Additionally the erythrocytic transketolase activity (ETK) and alphaETK
were determined as indicators of the cellular thiamine availability.
After benfotiamin ingestion a more rapid and earlier increase of
thiamine in plasma and hemolysate was observed in contrast to
fursultiamin and the disulfide. All biokinetic data demonstrated a
significantly improved thiamine bioavailability from benfotiamin
compared with the other preparations. The lowest bioavailability was
detected with thiamindisulfide. From our results it can be concluded
that oral administration of benfotiamin is best suitable for
therapeutical purposes owing to its excellent absorption
characteristics.
Publication Types:
- Clinical Trial
- Randomized Controlled Trial
PMID: 9587048 [PubMed -
indexed for MEDLINE]
|